Summit closes license deal for antibody therapy for most cancers; $500M rights offering on track

Shot of a businessman and businesswoman shaking hands in a modern office

Delmaine Donson

Summit Therapeutics (NASDAQ:SMMT) accomplished a deal to in-license Akeso bispecific antibody ivonescimab for most cancers.

Cambridge, Mass.-based Summit had signed the licensing settlement in December 2022 to obtain the rights to develop and commercialize ivonescimab within the U.S., Canada, Europe, and Japan. Meanwhile, Hong Kong-listed

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!